Home > Neurology > AAN 2019 > Stroke > Direct oral anticoagulants compared to vitamin K antagonist in atrial fibrillation -related cerebral ischemia

Direct oral anticoagulants compared to vitamin K antagonist in atrial fibrillation -related cerebral ischemia

Conference
AAN 2019
Trial
ARISTOPHANES
There is still only limited real-world evidence on comparative effectiveness and safety of direct oral anticoagulants (DOACs) – also referred to as non-vitamin K antagonist oral anticoagulants (NOACs) – versus a vitamin K antagonist in atrial fibrillation. In two studies to fill this gap, DOACs were found to result in a lower risk of intracranial haemorrhage [1,2]. In a retrospective subgroup analysis of the ARISTOPHANES study, stroke/systemic embolism, major bleeding, and their respective components were compared among non-valvular atrial fibrillation patients on DOACs or warfarin [1]. DOACs prescribed were apixaban, dabigatran, or rivaroxaban. Pooled results for two doses were presented: standard NOAC doses and warfarin (5 mg twice-daily apixaban-warfarin, 150 mg twice-daily dabigatran-warfarin, and 20 mg once-daily rivaroxaban-warfarin), and lower NOAC doses and warfarin (2.5 mg twice-daily apixaban-warfarin, 75 mg twice-daily dabigatran-warfarin, and 1...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on